3.72
+0.54%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fulcrum Therapeutics
From its filings with the US Securities and Exchange Commission
Fulcrum Therapeutics is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker FULC. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $74.9m. At that date it held total assets of $366.3m and shareholders' equity of $349.0m.
We are a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need.
Our lead product candidate, pociredir, is an oral small molecule designed to induce fetal hemoglobin, or HbF, and is in clinical development for the treatment of sickle cell disease, or SCD. We completed dosing in the PIONEER trial, a Phase 1b clinical trial evaluating pociredir in adults with SCD. The PIONEER trial included 12 mg and 20 mg once-daily dose cohorts, and evaluated subjects over a 12-week treatment period. We have reported clinical data demonstrating clinically relevant HbF induction, including progression toward pan-cellular distribution, and improvements in markers of hemolysis and anemia. We are currently activating sites in an open-label extension trial to evaluate longer-term safety and pharmacodynamic, or PD, durability in patients who completed the PIONEER trial. We plan to provide details regarding the design of the next trial in the second quarter of 2026 following receipt of meeting minutes from our End-of-Phase meeting with the FDA. Pending feedback from the FDA, we plan to initiate a potential registration-enabling trial in the second half of 2026.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Jul 2019
- Employees
- 55
- Website
- fulcrumtx.com ↗
- Head office
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Kate HavilandIndependent Chairman of the Board$249,059
- Mr. Alex SapirPresident, Chief Executive Officer, Director, since 2023$1.0m
- Mr. Alan MussoChief Financial Officer$1.3m
- Mr. Curtis OltmansChief Legal Officer$1.4m
- Ms. Sonja BanksIndependent Director$214,036
- Ms. Katina DortonIndependent Director$227,559
- Dr. Alan EzekowitzIndependent Director$222,559
- Mr. James GeraghtyIndependent Director$223,059
- Dr. Robert GouldIndependent Director, since 2016$217,559
- Mr. Colin HillIndependent Director$363,963
- Ms. Rachel KingIndependent Director$188,274
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 69
- Environment
- 74
- Social
- 76
- Governance
- 56
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Fulcrum Therapeutics Inc has a strong network of partnerships with leading pharmaceutical companies, enabling access to resources and expertise.
- The company has a robust pipeline of potential therapeutics targeting various genetic diseases, offering potential for significant revenue growth.
- Fulcrum Therapeutics has a highly skilled and experienced research and development team, capable of driving innovative approaches to drug discovery.
Weaknesses
- One of the weaknesses of Fulcrum Therapeutics is its heavy reliance on partnerships, which may limit the company's control over its product development and commercialization.
- The company's focus on genetic diseases may limit its market potential compared to pharmaceutical companies targeting broader therapeutic areas.
- As a relatively new company, Fulcrum Therapeutics may face financial constraints and a smaller operating budget compared to more established competitors.
Opportunities
- The increasing prevalence of genetic diseases and advancements in genetic research provide a favorable market environment for Fulcrum Therapeutics to capitalize on.
- Expanding strategic partnerships and collaborations can enhance the company's access to resources and expedite the development and commercialization of potential therapeutics.
- Global healthcare trends, such as the focus on personalized medicine, provide opportunities for Fulcrum Therapeutics to position itself as a leader in genetic-based treatments.
Threats
- Fulcrum Therapeutics operates in a highly competitive industry, facing potential competition from both established pharmaceutical companies and emerging biotech startups.
- Regulatory hurdles and a lengthy drug development process pose risks to the timely commercialization of Fulcrum Therapeutics' potential therapeutics.
- Changes in healthcare policies and reimbursement systems can impact the pricing and demand for genetic-based treatments, potentially affecting the company's revenue streams.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.